Investing in health care’s technological transformation

While the world has yet to fully emerge from the coronavirus pandemic, the remarkable success of the vaccine programme it initiated has already marked a milestone in the history of medical science and the health care industry. At T. Rowe Price, we see the rapid development of vaccines—particularly those using novel messenger ribonucleic acid (mRNA) technology—as only one part of a larger step change in the pace of medical discovery. In our view, the wave of innovation we expect over the coming decade offers a range of opportunity for patient and selective investors.